Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 14, 2018 - Issue 3: Special Issue on Influenza Vaccines, commemorating the 100th anniversary of Pandemic Flu
Submit an article Journal homepage
1,834
Views
12
CrossRef citations to date
0
Altmetric
Research Paper

Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea

Won Suk ChoiDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea
,
Ji Yun NohDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea
,
Jacob LeeDivision of Infectious Diseases, Department of Internal Medicine, Hallym University College of Medicine, Seoul, Republic of Korea
,
Jun Yong ChoiDivision of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
,
Jin-Soo LeeDivision of Infectious Diseases, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea
,
Moo Soo KimSanofi Pasteur, Regulatory Affairs, Seoul, Republic of Korea
,
Hee Soo KimSanofi Pasteur, Global Medical Affairs, Seoul, Republic of Korea
,
Joon BangSanofi Pasteur, Global Medical Affairs, Seoul, Republic of Korea
,
Nathalie LavisSanofi Pasteur, Medical Operations, Lyon, France
&
Woo Joo KimDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of KoreaCorrespondence[email protected]
 show all
Pages 587-592 | Received 11 May 2017, Accepted 14 Sep 2017, Published online: 17 Nov 2017

References

  • Park M, Wu P, Goldstein E, Kim WJ, Cowling BJ. Influenza-Associated Excess Mortality in South Korea. Am J Prev Med. 2016;50:e111-9. doi:10.1016/j.amepre.2015.09.028.
  • Suh M, Kang DR, Lee DH, Choi YJ, Tchoe B, Nam CM, Kim HJ, Lee JK, Jun BY, Youm Y, et al. Socioeconomic burden of influenza in the Republic of Korea, 2007–2010. PLoS One. 2013;8:e84121. doi:10.1371/journal.pone.0084121.
  • Kim YT. Current situation and elimination plan of influenza. J Korean Med Assoc. 2004;47:1116-28. doi:10.5124/jkma.2004.47.11.1116.
  • Oh MD, Lee JK. Milestones in history of adult vaccination in Korea. Clin Exp Vaccine Res. 2012;1:9-17. doi:10.7774/cevr.2012.1.1.9. doi:10.7774/cevr.2012.1.1.9.
  • Yang HJ, Cho SI. Influenza vaccination coverage among adults in Korea: 2008–2009 to 2011–2012 seasons. Int J Environ Res Public Health. 2014;11:12162-73. doi:10.3390/ijerph111212162.
  • Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines. 2013;12:1085-94. doi:10.1586/14760584.2013.824709. PMID:24024871.
  • Centers for Disease Control and Prevention. Past Weekly Surveillance Reports. 2017 [accessed 2017 May 9]. http://www.cdc.gov/flu/weekly/pastreports.htm.
  • Public Health Agency of Canada. Statement on seasonal influenza vaccine for 2014–2015. 2014 [accessed 2016 Aug 29]. http://www.phac-aspc.gc.ca/naci-ccni/flu-grippe-eng.php.
  • Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8:81-8. doi:10.4161/hv.8.1.17623.
  • Pepin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 2013;31:5572-8. doi:10.1016/j.vaccine.2013.08.069. PMID:24016810
  • Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Vaccine. 2015;33:2485-92. doi:10.1016/j.vaccine.2015.03.065.
  • Pepin S, Szymanski H, Rochin Kobashi IA, Villagomez Martinez S, Gonzalez Zamora JF, Brzostek J, Huang LM, Chiu CH, Chen PY, Ahonen A, et al. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study. Hum Vaccin Immunother. 2016;12(12):3072-8. doi:10.1080/21645515.2016.1212143.
  • Committee for Medicinal Products for Human Use. Note for guidance on harmonisation of requirements for influenza vaccines. 1997 [accessed 2017 May 9]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf.
  • Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, Belshe RB. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J. 2012;31:745-51. doi:10.1097/INF.0b013e31825687b0.
  • Sheldon EA, Jeanfreau R, Sliman JA, Charenkavanich S, Rousculp MD, Dubovsky F, Mallory RM. Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*. Influenza Other Respir Viruses. 2013;7:1142-50. doi:10.1111/irv.12027. PMID:23061976
  • Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31:770-6. doi:10.1016/j.vaccine.2012.11.074.
  • International Conference on Harmonization. Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. 1994 [accessed 2017 May 9]. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.